Gervasio A. Lamas

Aug 14, 2024 | jamanetwork.com | Gervasio A. Lamas |Miami Beach |Kevin J. Anstrom |Ana Navas-Acien

Key PointsQuestion  Does therapy with edetate disodium (EDTA)–based chelation reduce major adverse cardiovascular events compared with placebo infusions among patients with diabetes and prior myocardial infarction (MI)? Findings  EDTA-based chelation did not reduce major adverse cardiovascular events compared with placebo infusion, with a hazard ratio of 0.93 (95% CI, 0.76-1.16; P = .53).

Aug 14, 2024 | jamanetwork.com | Gregory Curfman |Gervasio A. Lamas |Kevin J. Anstrom |Ana Navas-Acien

Edetate Disodium–Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes Gervasio A. Lamas, MD; Kevin J. Anstrom, PhD; Ana Navas-Acien, MD, PhD; Robin Boineau, MD, MA; Hayley Nemeth, MS; Zhen Huang, MS; Jun Wen, MS; Yves Rosenberg, MD, MPH; Mario Stylianou, PhD; Teresa L. Z. Jones, MD; Bonnie R. Joubert, PhD, MPH; Qilu Yu, PhD; Regina M. Santella, PhD; Ana C. Mon, MPH; Francisco Ujueta, MD, MS; Esteban Escolar, MD; David M. Nathan, MD; Vivian A. Fonseca, MD; Y.

Apr 7, 2024 | healio.com | Katie Kalvaitis |Richard Smith |Gervasio A. Lamas |Suzanne J. Baron

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Chelation therapy involves IV infusions of an agent that binds to metals such as lead and cadmium and is excreted in urine. Chelation therapy did not yield clinical benefit in post-MI patients with diabetes.